CiPA In Silico Modeling
One of the aims of the CiPA initiative is to integrate data from patch-clamp experiments on a range of important ion channels with in silico simulations of cardiac electrical activity. In the second component of CiPA screening, electrophysiology data generated using the expanded panel of six ion channels is incorporated into an in silico human ventricular action potential model. However, the acquisition of advanced software suites and massive computing capabilities are available to anyone with resources they are willing to invest. What makes the real difference is experience. Here at Creative Bioarray, we are ready to support our customers in silico modeling. With our simulations we can help to make sense of your data.
Fig. 1 Explanatory examples of in silico drug trial results in a population of human computational models, showing drug-induced changes on APD90 and dV/dtMAX (left and right column, respectively) for 5 compounds (Dofetilide I, Flecainide I, Nimodipine, Ranolazine I and Verapamil II)
In silico models of cardiac electrical activity have become very sophisticated in recent years, and allow a better understanding of the complex non-linear interactions between the different ionic currents and ion concentrations within the cell. Readout from the model predicts changes in the action potential duration, a surrogate marker for QT prolongation, and generation of early after depolarizations (EADs) – with appearance of EADs being highly indicative of proarrhymic liability.
Creative Bioarray will provide you with:
General advice on in silico modeling of cardiac electrical activity.
Implementation of a range of available cellular models.
Disease state modeling (e.g. hypertrophic cardiomyopathy, ischemia, long-QT syndromes).
Implementing ion channel block based on electrophysiology data, plotting and interpretation of results.
Creative Bioarray has long experience in drug discovery. Scientists in Creative Bioarray have long tenure as a collaborative group and a very high level of collective expertise with in silico drug discovery. Within Creative Bioarray CiPA Customized Project, we will greatly reduce the time to identify and optimize drug candidates.
Reference
- Cardiotoxicity P, et al. Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical. Front Physiol. 2017; 8: 1–15.
Inquiry
